Clinical Pharmacogenetics Implementation Consortium Guidelines for  HLA‐B  Genotype and Abacavir Dosing: 2014 Update | Zendy

Martin M A | Zendy; Hoffman J M | Zendy; Freimuth R R | Zendy; Klein T E | Zendy; Dong B J | Zendy; Pirmohamed M | Zendy; Hicks J K | Zendy; Wilkinson M R | Zendy; Haas D W | Zendy; Kroetz D L | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing: 2014 Update

Author(s) -

Martin M A,

Hoffman J M,

Freimuth R R,

Klein T E,

Dong B J,

Pirmohamed M,

Hicks J K,

Wilkinson M R,

Haas D W,

Kroetz D L

Publication year - 2014

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.2014.38

Subject(s) - dosing , pharmacogenetics , abacavir , guideline , medicine , clinical pharmacology , pharmacology , genotype , family medicine , biology , genetics , human immunodeficiency virus (hiv) , pathology , antiretroviral therapy , viral load , gene

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing were originally published in April 2012. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplementary Material online and included additional resources for applying CPIC guidelines to the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research